Which Institute of Medicine quality dimension does a hospital's new electronic system for timely HbA1c (Hemoglobin A1c) testing and follow-up for diabetic patients primarily address?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Institute of Medicine Quality Dimension: Effectiveness

The electronic system for timely HbA1c testing and follow-up primarily addresses the Effectiveness dimension of the Institute of Medicine's quality framework, as it aims to ensure evidence-based care is delivered consistently to achieve the desired clinical outcome of improved glycemic control.

Understanding the IOM Quality Dimensions

The Institute of Medicine defines six quality dimensions for healthcare:

  • Effectiveness: Providing services based on scientific knowledge to all who could benefit, avoiding underuse
  • Efficiency: Avoiding waste of resources
  • Patient-centeredness: Providing care that is respectful and responsive to individual preferences
  • Equity: Providing care that does not vary in quality based on personal characteristics
  • Timeliness: Reducing waits and harmful delays
  • Safety: Avoiding injuries from care intended to help

Why This Intervention Addresses Effectiveness

The electronic system ensures diabetic patients receive evidence-based HbA1c testing at appropriate intervals, which is the cornerstone of effective diabetes management. 1, 2

Evidence-Based Testing Intervals

  • The American Diabetes Association recommends HbA1c testing at least twice per year in patients meeting treatment goals with stable glycemic control, and quarterly in those whose therapy has changed or who are not meeting glycemic goals 2
  • HbA1c is the primary metric for assessing long-term glycemic control, reflecting average glycemia over approximately 3 months, with strong predictive value for diabetes complications 2
  • The metric has high-quality evidence from clinical trials demonstrating the benefits of improved glycemic control 2

System Impact on Clinical Outcomes

Electronic systems that ensure timely testing have demonstrated measurable improvements in diabetes care:

  • An HbA1c tracking tool sent to primary care physicians for patients with HbA1c >7% resulted in improved glycemic control, with the strongest effect in patients with poorest control (HbA1c >9% dropped from 10.1% to 9.3%) 3
  • Electronic case management systems reduced diabetes-related crises approximately threefold and decreased HbA1c by 0.8% at 6 months and 0.9% at 12 months 4
  • Patients receiving timely medical intervention through electronic systems had reduced incidence of diabetic crises and fewer clinic visits 4

Why Other Dimensions Are Less Applicable

Efficiency would be the secondary benefit, as the system may reduce waste by automating reminders, but the primary goal is ensuring appropriate care delivery, not resource optimization 1

Patient-centeredness is not the primary focus, as the intervention is system-level rather than individualized to patient preferences 1

Equity would only apply if the system specifically targeted disparities in care delivery across different patient populations, which is not indicated in the question 1

Clinical Context

The intervention represents a quality improvement strategy that addresses the known gap between guideline recommendations and actual practice:

  • National quality programs include HbA1c control measures as core diabetes quality metrics 1
  • Electronic systems facilitate adherence to evidence-based guidelines by providing automated tracking and follow-up 1, 3
  • Timely HbA1c testing enables appropriate treatment adjustments to prevent long-term complications 2, 5

Answer: B - Effectiveness

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Assessing Glycemic Control in Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.